General
Preferred name
BEDAQUILINE
Synonyms
TMC 207 ()
R403323 ()
TMC-207 ()
TMC207 ()
R-403323 ()
R 403323 ()
R207910 ()
Bedaquiline (TMC-207) ()
BEDAQUILINE FUMARATE ()
Bedaquiline (fumarate) ()
TMC207 fumarate ()
R207910 fumarate ()
TMC-207, R207910 ()
R-207910 ()
Bedaquilina ()
Sirturo ()
P&D ID
PD009177
CAS
654653-93-7
843663-66-1
845533-86-0
Tags
available
drug
Approved by
PMDA
FDA
First approval
2012
Drug indication
Multi-drug resistant tuberculosis
Tuberculosis
Pulmonary tuberculosis
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ABSORPTION Tmax, oral dose = 5 hours;; Food increases the oral bioavailability. AUC increases proportionally up to the highest dose studied in healthy volunteers. When 400 mg of bedaquiline is administered once daily for a week, the peak plasma concentration (Cmax) is 5.5 μg/ml and an AUC of 64.75 μgh/ml.
DESCRIPTION Bedaquiline is a quinoline-based antimycobacterial drug that is used in the treatment of tuberculosis . Functionally, it inhibits mycobacterial ATP synthase and enhances the antibacterial activity of second-line drug combinations. (GtoPdb)
DESCRIPTION Bedaquiline (TMC207) is a diarylquinoline agent and inhibits Mycobacterium tuberculosis (Mtb) F1FO-ATP synthase through targeting of both the c- and the ¦Å-subunit[1]. Bedaquiline has uncoupler activity. Bedaquiline is used for the multi-agent resistant tuberculosis[2].
PRICE 75
DESCRIPTION Bedaquiline fumarate, a diarylquinoline antibiotic that targets ATP synthase, is effective for the treatment of Mycobacterium tuberculosis infections.
PRICE 81
DESCRIPTION Bedaquiline (R207910) is an anti-tuberculosis drug which selectively inhibit the mycobacterial energy metabolism i.e. ATP synthesis and found to be effective against all states of Mycobacterium tuberculosis. (TargetMol Bioactive Compound Library)
DESCRIPTION Bedaquiline fumarate (TMC207), a diarylquinoline antibiotic that targets ATP synthase, is effective for the treatment of Mycobacterium tuberculosis infections. It blocks the proton pump for ATP synthase of mycobacteria. It is the first member of a new class of drugs called diarylquinolines. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
2
Compound Sets
21
AdooQ Bioactive Compound Library
A12327
A17444
Cayman Chemical Bioactives
20247
ChEMBL Approved Drugs
CHEMBL376488
CHEMBL2105700
ChEMBL Drugs
CHEMBL376488
CHEMBL2105700
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB08903
DrugBank Approved Drugs
DB08903
DrugCentral
4741
DrugCentral Approved Drugs
4741
DrugMAP
DM3906J
DrugMAP Approved Drugs
DM3906J
EU-OPENSCREEN Bioactive Compound Library
EOS100719
Guide to Pharmacology
11171
MedChem Express Bioactive Compound Library
HY-14881
HY-14881A
NCATS Inxight Approved Drugs
78846I289Y
Pandemic Response Box
ReFrame library
Selleckchem Bioactive Compound Library
bedaquiline
bedaquiline-fumarate
TargetMol Bioactive Compound Library
T2585
T21023
The Pathogen Box
External IDs
51
Properties
(calculated by RDKit )
Molecular Weight
554.16
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
8
Ring Count
5
Aromatic Ring Count
5
cLogP
7.13
TPSA
45.59
Fraction CSP3
0.22
Chiral centers
2.0
Largest ring
6.0
QED
0.22
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Disease
REFERENCE COMPOUNDS
Target
antibiotic
Bacterial
Tubercle bacillus
ATPase
Indication
tuberculosis
MOA
ATPase inhibitor
Pathway
Microbiology/virology
Anti-infection
Source data